California Stem Cell Report
News, information and commentary on public policy and business issues involving California's new stem cell agency, the California Institute for Regenerative Medicine, created by Prop. 71. This Web page is published by David Jensen, whose background and email contact can be found on this page under oddly titled section, "About Me."
Friday, October 19, 2007
Position Change: CIRM Now Permitting Public Comment at $85 Million Hearing
The California stem cell agency today reversed itself and decided to permit public comments prior to two days of closed hearings next week on requests for $85 million in grants to California researchers.
The change in position came quietly today as the agency posted a new agenda for the hearings on the CIRM web site that did not mention that it had been revised. The new posting specifically stated that public comment would be allowed. It also removed this sentence from the agenda::
"An open session will not be held for the meeting of October 23-24, 2007 as business will be limited to review of grant applications.The change in public access followed disclosure earlier today by the California Stem Cell Report of the ban and subsequent complaints by at least one member of the CIRM Oversight Committee, David Serrano Sewell (see item below)."
Labels: CIRM management, CIRM overview, CSCR, faculty grants, openness
Comment on Ban on Public at $85 Million CIRM Meeting
David Serrano Sewell, a member of the CIRM Oversight Committee, sent the following on the "Public Barred" item below.
"Just read your item regarding the public being barred from the upcoming Grants Working Group meeting. To my recollection, those agendas have always included an opportunity for the public to address the working group. The failure to include such an item for this agenda was probably a honest mistake that must be corrected. I (and the the patient advocate working group members) support the public attendance at working group meetings. Thanks for catching this!"Our comment: The agenda for the meeting in question contains a sentence that we cannot recall ever seeing before on a CIRM agenda:
"An open session will not be held for the meeting of October 23-24, 2007 as business will be limited to review of grant applications."
Labels: CIRM management, CIRM overview, faculty grants, openness
Interstate Stem Cell Issues Coming Up in Public Session Next Week
The Interstate Alliance for Stem Cell Research, which once ousted a member of the public from a meeting in California, will hold two days of open public meetings in Massachusetts next Wednesday and Thursday.
The agenda (see item below) for the group, operating under the auspices of the National Academy of Sciences, includes a host of major issues that states are grappling with across the country. They include model language for the term "acceptably derived," payment issues and health care for egg donors, certification of stem cell lines from other states and countries and the grant review process.
We applaud the decision to make the meeting public. Billions of dollars in public resources are involved along with the need to maintain confidence in embryonic stem cell research. Closed door meetings and secret processes generate suspicion and encourage the worst sort of speculation.
John M. Simpson, stem cell project director for the Foundation for Taxpayer and Consumers Rights, was the man ousted from last May's meeting. He says,
"I'm glad to see the change of heart. Too often the scientific establishment has displayed a paternalistic 'trust-us-we-know-best' attitude that in fact undercuts public support for science. Scientists need to engage and educate, otherwise we end up with the know-nothing attitude too often exemplified by the current administration. "
Labels: interstate cooperation, openness
Agenda for Public Meeting on Interstate Stem Cell Issues
Here is the agenda for next week's public interstate stem cell meeting.
Interstate Alliance for Stem Cell Research
British Consulate
Cambridge, MA
October 24-25, 2007
Agenda
October 24
12:00 pm Lunch (at Consulate)
1 pm Welcome and Introductions
Warren Wollschlager, Chair, Office of Research and Development, State of Connecticut and Fran Sharples, National Academies’ Secretariat for IASCR
Introduction of other participants
The purpose of this meeting is to review progress on the working group assignments made at the May 23-24 Irvine, CA meeting and to identify additional issues the IASCR needs to address.
1:15 pm Governance Issues - preliminary discussion: Warren Wollschlager
1:30 pm Report of Working Group on the development of a Glossary of Stem Cell Terms: William Lensch (Tab 1)
2:15 pm Report of Working Group on an IASCR Website: Fran Sharples, Susan Stayn, Eli Zupnick (Tab 2)
3:00 pm Break
3:15 pm Report of Working Groups on Developing Model Language for “Acceptably Derived;†Payment Issues and Health Care for Donors; and Certification of Stem Cell Lines from Other States and Countries (formation of standing committee): Marianne Horn, Geoff Lomax, Melissa Lopes, Susan Stayn, Ann Willey, Eileen Naughton, and Alta Charo (by phone) (Tab 3)
5:15 pm Adjourn meeting for the day
6:00 pm Reception (on site)
October 25
8:30 am Breakfast (at Consulate)
9:00 am Report of Working Group on Grant Reviews: Marianne Horn, Warren Wollschlager (Tab 4)
9:45 pm Report of Working Group of Legal Counsels on Role of Regulations vs. Guidelines and Policy Documents: Marianne Horn (Tab 5)
10:30 am Break
10:45 am Summary discussion of Working Group next steps
12:00 pm Working Lunch: Roles of International Society for Stem Cell Research: Jonathan Auerbach and Heather Rooke (Tab 6)
1:15 pm Governance Issues
Officers
Membership in IASCR
Budget
Roles of IASCR: information resource vs. policy development
Product branding
2:00 pm Recruitment of additional states and other members: discussion
2:30 pm Break
2:45 pm Working Group breakouts
3:30 pm Other agenda items TBD
4:00 pm Adjourn
Labels: interstate cooperation, openness
Public Barred from Any Comment at $85 Million CIRM Meeting
Two days of closed-door meetings will be held in the San Francisco Bay area next week to consider the 59 applications for $85 million in faculty award grants to be handed out in December by the California stem cell agency.
The agency's Grants Working Group will meet next Tuesday and Wednesday at the Sheraton Gateway Hotel in Burlingame to make decisions on which grants to recommend to the Oversight Committee.
The agenda explicitly states there will be no open sessions at which the public can comment. That bars the public from even appearing to protest or comment on the lack of public access, which seems to be the first such ban by CIRM, an agency that has vowed to uphold the highest standards of openness and transparency. Previously, such meetings, including the very sensitive meetings involving the search for a new president, have included at least a brief session during which the public could comment.
Here is a list of the members of the Working Group, whose economic and professional links to applicants are secret. Also being withheld by CIRM decree are the names of the applicants for the state funding and even the institutions (including state-funded universities) where they are employed along with a general summary of the research they are proposing.
The Oversight Committee is scheduled to give out as many as 25 awards, making the odds pretty good for the 59 applicants. The awards could total as much as $3 million a year. Twenty-eight unnamed organizations are represented among employers of the individual applicants.
Labels: CIRM management, CIRM overview, conflicts, faculty grants, openness
Wednesday, October 17, 2007
Aussie Stem Cell Probe Highlights Need for Maximum Openness at CIRM
John M. Simpson, stem cell project director for the Foundation for Taxpayer and Consumers Rights of Santa Monica, Ca., is one of the more diligent watchdogs of the California stem cell agency, which is funded by taxpayers to the tune of roughly $6 billion (including interest).
Simpson (see photo) and his organization support human embryonic stem cell research, but they also have concerns about CIRM, an organization unlike any other in California history. It is virtually untouchable by the governor or the legislature, a distinction enjoyed by no other state agency.
CIRM is also an organization with built-in conflicts of interest, all legal because they were approved by California voters in Prop. 71, which created the stem cell agency.
We believe that means that CIRM should operate with more disclosure and openness than any other state agency. Such openness is in CIRM's own best interest, given the impact that even a minor scandal might have.
All that is a preface to Simpson's comments below, carried verbatim, on the Australian-Trounson stem cell research inquiry(see the several items below). Here is what Simpson sent exclusively to the California Stem Cell Report.
"As word makes its way from Australia to the United States about an investigation of a researcher in Alan Trounson's Monash Immunology and Stem Cell Laboratories, one point is already clear.
"There must be complete transparency and accountability in publicly funded research.
"Trounson, who is to assume the presidency of the California Institute for Regenerative Medicine, is by all accounts not under investigation. A report from a panel of academics who examined the evidence of wrongdoing is 'imminent.'
"Everyone interested in California's stem cell program is waiting for that report to see what degree of culpability -- if any -- Trounson had for things apparently done by others in his laboratory.
"Even before the report's release, the situation once again demonstrates the need for oversight, transparency and accountability in scientific research. Time and time again around the world, too many scientists have bent the rules for their own personal gain. Research simply must not be funded without the highest degree of public scrutiny.
"CIRM staff demonstrated the necessary high standards when after its vetting process, two ICOC-approved research awards were not granted.
"I suspect Trounson will emerge from the Monash probe unscathed, and I hope it will be with an even stronger commitment to the standards of accountability and transparency required by CIRM.
"Nonetheless, the ICOC should review closely the Monash University report when it is available and not allow itself to be blinded by the glitter of a world-class researcher. Even before the report's details emerge, however, the need for transparency and openness in all aspects of publicly funded research is demonstrated yet again."
Labels: CIRM overview, openness, scientific culture
Does the Trounson Story Have Legs?
The Australian stem cell research flap involving Alan Trounson made its North American debut today in a story in the San Francisco Chronicle. It also surfaced in one of the more serious scientific magazines, the Scientist.
Stephen Pincock of the Scientist added some details on the research. He also indicated a conclusion to the investigation is imminent. Sabin Russell's story in the Chronicle pretty much recapped previous material.
A reader on the Scientist web site, only identified as Leah, commented, "Why are there so many scandals around stem cell research? What a waste of money."
A quick resolution of the investigation is in the best interest of the California stem cell agency and Trounson, the incoming president of the $3 billion enterprise. As the saying goes, justice delayed is justice denied. The other important point is whether this story has legs. Trounson is not the subject of the investigation, but his name is really what makes it newsworthy. And it is mentioned in every story. The longer the story lingers, the more often Trounson's name will be associated with allegations of dubious activity. Not good for either the agency or Trounson.
Labels: media coverage, scientific culture
Tuesday, October 16, 2007
Trounson Reports Not Appearing in American Mainstream Media
For the California stem cell agency, the good news is that the Australian stories about an investigation linked peripherally to its incoming president, Alan Trounson, have not really surfaced in the United States.
The usual online searches today failed to turn up any significant stories on the matter in the mainstream American media.
The not-so-good news is that the stories have handed another cudgel to those who would batter embryonic stem cell research. The case in point is an item by J. Wesley Smith(see photo), whose piece was headlined, "New CIRM Director's Research Under a Potential Cloud."
However, after some initial fumbling, the Australian stories have made it clear that Alan Trounson is not under investigation. Rather, another senior scientist involved in the $1.2 million project is the target, according to Australian officials.
The Australian, in a story by Leigh Dayton quoted California stem cell Chairman Robert Klein on the matter.
"I am fully aware of this and it is not Alan's work that is being questioned. My understanding is that this is a data issue that relates to the science carried out by a specific researcher."Dayton wrote that Klein "solidly backed" Trounson. Dayton reported that Klein said that Trounson discussed the matter with the presidential search committee prior to his appointment.
One report from Australia quoted a CIRM spokesman as saying, "We're aware of the situation and have it under careful review." Interim CIRM President Richard Murphy confirmed, for the California Stem Cell Report, that was the agency's position.
Reporter Dan Box of the Australian wrote that Monash University is tossing out all the data from the experiment. He also quoted Monash officials as saying it is not known when the nine-month-old investigation will be finished.
Dayton wrote this about the details of the project.
Specifically, "benchmarking" reports claimed the group had developed a designer mouse that mimicked lung damage from smoking.
The reports also claimed the team had experimental results showing that treatment with adult stem cells reversed respiratory damage in the mouse.
According to the ASCC investigation, neither claim was supported by documentation in the lab's notebooks.
Labels: media coverage, presidential search, scientific culture
Fresh Comment
David Hamilton has posted a comment on the "Buried News" item below. You can read it by clicking on the word "comments" at the end of the item.
Labels: CSCR
Sunday, October 14, 2007
Buried News: William Bowes, UCSB and Jamie Thomson
In the increasingly rarefied atmosphere of stem cell philanthropy, a $3 million gift does not necessarily make big headlines. Especially when it goes to a school outside of the small circle of stem cell stars.
So last week when one of the founders of Amgen, William Bowes(see photo), gave that amount to the University of California campus at Santa Barbara(UCSB)
Something similar occurred earlier this year when renown University of Wisconsin stem cell researcher Jamie Thomson became affiliated as an unpaid, adjunct professor with UCSB. It was nearly a non-announcement and received little initial attention. But the school put together a $1 million package for him and is building a lab.
All of which reflects very much on the way the California media works. If it doesn't happen in Los Angeles or San Francisco, it is not likely to receive much notice.
But more particularly none of the news reports on the donation put it together with Thomson's presence at UCSB, which is very much a part-time thing. But it is hard to resist speculating that Thomson and UCSB could draw ever closer.
The press release from school, which stands on the cliffs overlooking the Pacific just north of Santa Barbara, quoted Michael Witherell, UCSB vice chancellor for research, as saying:
"UCSB is bringing to stem cell research its characteristic approach of integrating science and engineering in a single center. The Ruth Garland Chair is central to this approach, because it allows us to attract a researcher of national stature to lead the new center."The $3 million donation was given by Bowes in memory of his mother, Ruth Garland. She was born in Santa Barbara and raised in nearby Ojai. Her grandparents settled in Santa Barbara in 1855. Educated as a physican at Stanford , she participated in a major diabetics study with William Sansum in Santa Barbara. A nonprofit research facility in Santa Barbara bears his name. It was one of the first places in the United States to do studies on insulin after it was discovered.
We asked Dennis Clegg, chairman of the Department of Molecular, Cellular and Developmental Biology Department and director of the Training Program in Stem Cell Biology at UCSB, about the donation. He replied,
"The gift will allow us to bring in senior talent in the stem cell field to be director of a new center, which will allow us to build on our rapidly growing program in stem cell research, and we are really excited about it. We have had interest in the position from the US and abroad. We have already formed a search committee and will be inviting candidates for interviews in the near future."Incidentally, UCSB has received nearly $3.5 million in funding from the California stem cell agency during the past two years. You can see Thomson's talk that he gave at UCSB last spring by going to this web page.
Labels: news coverage, philanthropy, prop. 71 impact
Saturday, October 13, 2007
Australian News Story Erring on Details
An Australian news report about an investigation involving Alan Trounson and a stem cell research project is apparently not entirely correct on some of the details.
Here is what we have been told concerning Trounson's role on the project (see item below). Trounson was the leader of the respiratory research program, which had three principal investigators (PI) and 16 scientists. The person being investigated was a PI (senior research fellow).
The story in the Daily Telegraph did not make it clear that there were three PIs and as many 16 scientists.
Labels: scientific culture
Friday, October 12, 2007
Trounson Stem Cell Project Under Investigation in Australia
An Australian newspaper is reporting that Monash University is investigating "inconsistencies" in a $1 million research project involving Alan Trounson, the incoming president of the California stem cell agency.
Reporter Carly Crawford of the Daily Telegraph said the stem cell research project "is under investigation after it was scrapped for delivering highly doubtful results." Crawford quoted a university spokesman as saying the investigation involved "possible inconsistencies.
Trounson was quoted as saying through a spokesman,
"I will not comment on this matter while it is being investigated by the university."The newspaper said Trounson was not being investigated by Monash University but that he had been interviewed.
The matter involves interim findings from lung regeneration research conducted at Monash with public funds, according to Crawford, apparently from the Australian Stem Cell Center, which Trounson co-founded and which is scheduled to receive $115 million in government funding over a 10 year period.
According to the newspaper, Trounson was the principal investigator on the project, which involved 13 scientists. Investigators were required to submit 90-day progress reports to keep the grant funding flowing. The story said that "inconsistencies" were found by the Australian Stem Cell Center in multiple progress reports that were signed by Trounson and an unnamed senior researcher.
(Editor's note: Later information (see item above) indicated that Trounson was the leader of the respiratory research program, which had three principal investigators (PI) and 16 scientists. The person being investigated was a PI (senior research fellow).
The story did not make it clear when the inquiry began. It said that the Stem Cell Center referred findings to Monash last December. The story also said the project was abandoned in February after inconsistencies were found.
The newspaper said it "understands lab records contradicted assertions contained in the reports that said agreed research benchmarks had been met."
Labels: scientific culture
Fresh Comments
Larry Ebert has posted a new comment on the "Nobel" item below. David Jensen, the author of this blog, has posted a comment on the "CIRM Says No" item in response to the one by CIRM Oversight Committee member Jeff Sheehy. Sheehy's position is that the public disclosure of statements of economic interests by grant reviewers is not necessary. Our position is that we should not give the enemies of stem cell research any new cudgels. You can read the comments by clicking on the word "comments" at the end of the items.
Thursday, October 11, 2007
Nobel Prize, Stem Cells and WARF
Some of the reports earlier this week on the Nobel prize in medicine did not highlight its key link to human embryonic stem cell research or, indeed, how it plays into the WARF stem cell patent challenge.
The connection was something that initially eluded this sometimes science-challenged writer. But we asked Jeanne Loring of the Burnham Institute (soon to be of the neighboring Scripps Institute) to elucidate.
She said it was "a spectacular day" for embryonic stem cell researchers.
"The Nobel Prize for Physiology or Medicine was awarded to three pioneers in embryonic stem cell research. Dr. Martin Evans and his colleagues accomplished a scientific coup in 1981, creating the first embryonic stem (ES) cell lines. Dr. Mario Capecchi and Dr. Oliver Smithies developed a way to alter genes in the ES cells, and for the last 20 years, scientists have used these scientific procedures to create hundreds of valuable new strains of laboratory mice. Some of these mice contain human disease-causing mutations, and are used all over the world for research on cancers, obesity, diabetes, Alzheimer's disease, Huntington's disease, and dozens of other diseases. These mouse 'models' of human disease are invaluable for pharmaceutical development and have had a dramatic effect on accelerating the pace of new drug development.Loring is one those challenging WARF's patents on stem cells, a matter that has troubled some in the research community, including the incoming president of the California stem cell agency, Alan Trounson."
In April, Loring wrote an op-ed piece in the Wisconsin State Journal, commenting on the justification for the challenge and the early negative findings by the federal government.
She said,
"WARF's executives are understandably unhappy about the patent office's decision because they think they will lose money.(For unknown reasons, Loring's piece does not appear in a routine search of the Wisconsin newspaper. If you would like a copy, please send an email to djensen@californias
"But they could save an enormous amount of money, and gain a great deal of good will, by quietly dropping their claims to human embryonic stem cells and allowing the judgment of the patent office to stand. If they did this, they could be seen as a supporter, not an exploiter, of scientific research.
"If Sir Martin Evans of Scotland, who was one of those who first made embryonic stem cells in 1981, were to be awarded the Nobel Prize for his discovery, as is expected, WARF could gracefully take credit for helping scientists build on his landmark research."
Labels: scientific culture
Work to Begin on Stem Cell Training Grant Concepts
California stem cell agency officials seem ready to dissect a $31 million proposal to train thousands of persons to work in the stem cell industry and use it as the framework for competitive bidding on efforts to beef up the biotech workforce.
The proposal from the California State University and community college systems came up for a brief discussion at last week's Oversight Committee meeting.
Richard Murphy(see photo), interim CIRM president, told committee members that CIRM funds should be awarded on a competitive basis. However, he said more discussions will be held with officials at CSUS as the CIRM staff works out concepts for RFAs.
The CSUS and community college systems, assuming they remain focused on CIRM, are likely to win their share of the grants.
CSUS officials presented their plan to the Oversight Committee last August. No other options were laid out at the time, although Oversight Committee members raised a series of questions. CSUS responded with a lengthy report prior to last week's meeting.
Training is an important part of the CIRM's strategic plan. especially in the next year or two. The plan designated about $38 million for technical staff training and about $35 million for scientific personnel development.
The technical training component seems to be more aligned with the CSUS proposal. The plan stated:
"The growth of this industry will require an educated and well-trained workforce. CIRM will support training of technical staff with essential skills for stem cell research such as cell culture, microscopy, fluorescence-activated cell sorting and analysis, micromanipulation techniques, surgical techniques, and good laboratory practices (GLP). Training will be supported at the undergraduate and masters levels with certificate or degree programs. Successful biotechnology training programs have already been implemented at several California colleges and universities as a means of supporting the broader research community. CIRM will seek to support similar programs that focus efforts towards maintaining an adequate supply of technical staff for stem cell research.
Labels: biotech workforce, CIRM management
Change settings via the Web (Yahoo! ID required)
Change settings via email: Switch delivery to Daily Digest | Switch format to Traditional
Visit Your Group | Yahoo! Groups Terms of Use | Unsubscribe
.
__,_._,___
